{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:01:34Z","timestamp":1791284494112,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019921","name":"National Scleroderma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008590","name":"Dr Ralph And Marian Falk Medical Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009162","name":"Hairy Cell Leukemia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jaut.2025.103369","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T08:54:53Z","timestamp":1737276893000},"page":"103369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy"],"prefix":"10.1016","volume":"151","author":[{"given":"Vinayak","family":"Uppin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Troje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beau R.","family":"Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branden S.","family":"Moriarity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshmi","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2025.103369_bib1","first-page":"145","article-title":"Systemic lupus erythematosus\u20142005 annus mirabilis?. Nat. Clin. Pract","volume":"2","author":"Isenberg","year":"2006","journal-title":"Rheumatol."},{"key":"10.1016\/j.jaut.2025.103369_bib2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3390\/jcm9030712","article-title":"New horizons in the genetic etiology of systemic lupus erythematosus and lupus-like disease: monogenic lupus and beyond","volume":"9","author":"Demirkaya","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jaut.2025.103369_bib3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/rheumatology\/kep012","article-title":"Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort","volume":"48","author":"Danila","year":"2009","journal-title":"Rheumatol"},{"key":"10.1016\/j.jaut.2025.103369_bib4","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/art.39503","article-title":"MEDI\u2010551 treatment effectively depletes B cells and reduces serum titers of autoantibodies in mice transgenic for Sle1 and human CD19","volume":"68","author":"Gallagher","year":"2016","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103369_bib5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells","volume":"173","author":"Ng","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103369_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1471-4906(01)02159-7","article-title":"The role of BAFF in B-cell maturation, T-cell activation and autoimmunity","volume":"23","author":"Mackay","year":"2002","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jaut.2025.103369_bib7","first-page":"1004","article-title":"TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts","volume":"111","author":"Bossen","year":"2008","journal-title":"Blood, Am. J. Hematol."},{"key":"10.1016\/j.jaut.2025.103369_bib8","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.4049\/jimmunol.175.5.2814","article-title":"B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells","volume":"175","author":"Yang","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103369_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1196\/annals.1313.004","article-title":"BAFF overexpression is associated with autoantibody production in autoimmune diseasesAnn","volume":"1050","author":"Pers","year":"2005","journal-title":"N. Y. Acad. Sci."},{"key":"10.1016\/j.jaut.2025.103369_bib10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.cyto.2015.07.014","article-title":"The role of BAFF in the progression of rheumatoid arthritis","volume":"76","author":"Wei","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.jaut.2025.103369_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE)","volume":"20","author":"Mockel","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2025.103369_bib12","first-page":"259","article-title":"BAFF\/APRIL pathway in Sj\u00f6gren syndrome and systemic lupus erythematosus: relationship with chronic inflammation and disease activity","volume":"62","author":"Vadacca","year":"2010","journal-title":"Reumatismo"},{"key":"10.1016\/j.jaut.2025.103369_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4352","article-title":"B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis","volume":"15","author":"Francois","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2025.103369_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2249.2012.04653.x","article-title":"B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia","volume":"170","author":"Lake-Bakaar","year":"2012","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2025.103369_bib15","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.autrev.2013.03.011","article-title":"Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis","volume":"12","author":"Berrih-Aknin","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2025.103369_bib16","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1080\/00365520701452225","article-title":"Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease","volume":"42","author":"Fabris","year":"2007","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2025.103369_bib17","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/art.21138","article-title":"BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus","volume":"52","author":"Stohl","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103369_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000063","article-title":"BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year","volume":"2","author":"Zollars","year":"2015","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.jaut.2025.103369_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-019-1623-4","article-title":"Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis","volume":"20","author":"Friebus-Kardash","year":"2019","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.jaut.2025.103369_bib20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/0976-500X.85930","article-title":"Belimumab: first targeted biological treatment for systemic lupus erythematosus","volume":"2","author":"Dubey","year":"2011","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.jaut.2025.103369_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/03009742.2019.1603324","article-title":"Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting","volume":"48","author":"Anjo","year":"2019","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103369_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103369_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","article-title":"Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial","volume":"77","author":"Merrill","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103369_bib24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately\u2010to\u2010severely active systemic lupus erythematosus: the randomized, double\u2010blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103369_bib25","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2147\/DDDT.S195113","article-title":"Clinical efficacy and safety of rituximab in lupus nephritis","author":"Zhong","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jaut.2025.103369_bib26","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.27515","article-title":"Prolonged effects of short\u2010term anti\u2010CD20 B cell depletion therapy in murine systemic lupus erythematosus","volume":"62","author":"Bekar","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103369_bib27","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.4049\/jimmunol.1101629","article-title":"An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in lupus","volume":"187","author":"Ahuja","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103369_bib28","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2025.103369_bib29","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jaut.2025.103369_bib30","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2025.103369_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103369_bib32","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.4049\/jimmunol.1202317","article-title":"F. Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy","volume":"189","author":"Winter","year":"2012","journal-title":"J. Immn."},{"key":"10.1016\/j.jaut.2025.103369_bib33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.jaut.2025.103369_bib34","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103369_bib35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1136\/ard.2008.096495","article-title":"HLA-DRhigh\/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus","volume":"69","author":"Jacobi","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.jaut.2025.103369_bib36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/ard.2007.078402","article-title":"B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titers","volume":"67","author":"Ioannou","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103369_bib37","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.3389\/fimmu.2018.02673","article-title":"Long-lived plasma cells in mice and men","volume":"9","author":"Brynjolfsson","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103369_bib38","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.jaut.2025.103369_bib39","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3390\/life13071496","article-title":"Current treatment approach, emerging therapies and new horizons in systemic lupus erythematosus","volume":"13","author":"Athanassiou","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.jaut.2025.103369_bib40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaut.2012.05.010","article-title":"Bone marrow of NZB\/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity","volume":"39","author":"Mumtaz","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2025.103369_bib41","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103369_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-015-0551-3","article-title":"Long-lived plasma cells are early and constantly generated in New Zealand Black\/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors","volume":"17","author":"Taddeo","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2025.103369_bib43","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jdermsci.2013.11.007","article-title":"Differential expression of BAFF and its receptors in discoid lupus erythematosus patients","volume":"73","author":"Chong","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jaut.2025.103369_bib44","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/cti2.1047","article-title":"Analysis of serum B cell\u2010activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus","volume":"8","author":"Vincent","year":"2019","journal-title":"Clin. Transl. Immunology"},{"key":"10.1016\/j.jaut.2025.103369_bib45","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1038\/s41598-020-63390-0","article-title":"Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients","volume":"10","author":"Salazar-Camarena","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2025.103369_bib46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","article-title":"A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers","volume":"13","author":"Wong","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2025.103369_bib47","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1177\/0961203319868531","article-title":"Autoantibodies in SLE: prediction and the p value matrix","volume":"28","author":"Choi","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2025.103369_bib48","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/eji.201041354","article-title":"Plasma cells in systemic lupus erythematosus: the long and short of it all","volume":"41","author":"Liu","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jaut.2025.103369_bib49","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.0902592","article-title":"TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus","volume":"184","author":"Nickerson","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103369_bib50","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2025.103369_bib51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/08916934.2010.509122","article-title":"Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation","volume":"44","author":"Kim","year":"2011","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaut.2025.103369_bib52","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1177\/0961203310375268","article-title":"Expressions of BAFF\/BAFF receptors and their correlation with disease activity in Chinese SLE patients","volume":"19","author":"Zhao","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2025.103369_bib53","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.4049\/jimmunol.173.5.3524","article-title":"Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus","volume":"173","author":"Ramanujam","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103369_bib54","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1126\/science.1076071","article-title":"Maintenance of serological memory by polyclonal activation of human memory B cells","volume":"298","author":"Bernasconi","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jaut.2025.103369_bib55","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1186\/ar1009","article-title":"B cell abnormalities in systemic lupus erythematosus","volume":"5","author":"Grammer","year":"2003","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2025.103369_bib56","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"21","author":"Schmidts","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaut.2025.103369_bib57","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2025.103369_bib58","article-title":"Belimumab for systemic lupus erythematosus","volume":"2","author":"Singh","year":"2021","journal-title":"Cochrane Db Syst Rev"},{"key":"10.1016\/j.jaut.2025.103369_bib59","article-title":"Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study","volume":"10","author":"Walti","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaut.2025.103369_bib60","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.4049\/jimmunol.170.9.4818","article-title":"Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis","volume":"170","author":"Singh","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103369_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101375","article-title":"A protocol to evaluate immunoglobulin deposits in mouse glomeruli","volume":"3","author":"Nambadan","year":"2022","journal-title":"STAR protocols"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T23:06:20Z","timestamp":1740351980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841125000149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":61,"alternative-id":["S0896841125000149"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103369","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103369"}}